B&L buys Alaway
This article was originally published in The Tan Sheet
Executive Summary
Alimera Sciences and Bausch & Lomb announce Dec. 20 B&L has purchased Alimera's OTC allergy franchise, including recently-approved Alaway, for an undisclosed amount. "The acquisition of Alaway not only enhances our current OTC product portfolio by giving us a stronger and longer-lasting product to address the needs of consumers who suffer itchy eyes, but it also gives us an excellent technology platform for the development of product line extensions in the ocular allergy category," B&L Corporate VP and Global Pharmaceutical Category Leader Gary M. Phillips, M.D., says. Alimera Sciences announced FDA's approval of Alaway Dec. 5 (1"The Tan Sheet" Dec. 11, 2006, p. 7)...
You may also be interested in...
Alimera’s Alaway Follows Novartis’ Zaditor To Spring 2007 OTC Launch
Alimera Sciences plans to launch its Alaway over-the-counter ophthalmic solution at the same time as its bioequivalent competitor, Novartis' Zaditor.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.